The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which will negotiate prices with drug makers for certain high-cost, sole-source drugs and apply them beginning in 2026. Comments are due July 2.

Related News Articles

Headline
Senators Bill Cassidy, R-La., and Maggie Hassan, D-N.H., Nov. 1 released a policy framework detailing a plan to impose site-neutral payments on hospitals. Site…
Headline
The Centers for Medicare & Medicaid Services Oct. 29 announced the Medicare Shared Savings Program yielded a program-record of more than $2.1 billion in…
Headline
A report released OCt. 23 by Kodiak Solutions found that Medicare Advantage plans classified three to four times as many hospital stays as observation visits…
Headline
A report released Oct. 24 by the Office of Inspector General found that insurers received an estimated $7.5 billion in Medicare Advantage risk-adjustments for…
Headline
Medicare open enrollment for 2025 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Headline
The AHA Oct. 17 released its Health Care Plan Accountability Update, covering the latest developments in Medicare Advantage, legislation and regulation of…